MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 6, 2006; DOI: 10.1124/mol.106.026336


0026-895X/06/7004-1307-1318$20.00
Mol Pharmacol 70:1307-1318, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.026336v1
70/4/1307    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bartos, M.
Right arrow Articles by Bouzat, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bartos, M.
Right arrow Articles by Bouzat, C.

Molecular Determinants of Pyrantel Selectivity in Nicotinic Receptors

Mariana Bartos, Diego Rayes, and Cecilia Bouzat

Instituto de Investigaciones Bioquímicas, Universidad Nacional del Sur-Consejo Nacional de Investigaciones Científicas y Técnicas, Bahía Blanca, Argentina

Nicotinic receptors (acetylcholine receptors, AChRs) play key roles in synaptic transmission throughout the nervous system. AChRs mediate neuromuscular transmission in nematodes, and they are targets for antiparasitic drugs. The anthelmintic agents levamisole and pyrantel, which are potent agonists of nematode muscle AChRs, are partial agonists of mammalian muscle AChRs. To further explore the structural basis of the differential activation of AChR subtypes by anthelmintics, we studied the activation of {alpha}7 AChRs using the high-conductance form of the {alpha}7-5-hydroxytryptamine-3A receptor, which is a good model for pharmacological studies involving the extracellular region of {alpha}7. Macroscopic and single-channel current recordings show that levamisole is a weak agonist of {alpha}7. It is interesting that pyrantel is a more potent agonist of {alpha}7 than acetylcholine (ACh). To identify determinants of this differential activation, we replaced residues of the complementary face of the binding site by the homologous residues in the muscle {epsilon} subunit and evaluated changes in activation. The mutation Q57G does not affect the activation by either ACh or levamisole. However, it increases EC50 values and decreases the maximal response to pyrantel. Kinetic analysis shows that gating of the mutant channel activated by pyrantel is profoundly impaired. The decreased sensitivity of {alpha}7-Q57G to pyrantel agrees with its weak action at muscle AChRs, indicating that when glycine occupies position 57, as in the mammalian muscle AChR, pyrantel behaves as a partial agonist. Thus, position 57 located at the complementary face of the binding site plays a key role in the selective activation of AChRs by pyrantel.


Received May 4, 2006; accepted July 5, 2006

Address correspondence to: Dr. Cecilia Bouzat, Instituto de Investigaciones Bioquímicas, Camino La Carrindanga Km 7, B8000FWB, Bahía Blanca, Argentina. E-mail: inbouzat{at}criba.edu.ar







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics